Deutsch English Français

Contact

EP1022339

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1022339

EP1022339 - Plasmids, their construction and their use in the manufacture of interleukin-4 and interleukin-4 muteins [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 08.12.2006 Database last updated on 05.10.2024
Most recent event Tooltip	08.12.2006	No opposition filed within time limit	published on 10.01.2007 [2007/02]
Applicant(s)	For all designated states Bayer HealthCare AG 51368 Leverkusen / DE
	[2006/05]
Former [2004/02]	For all designated states Bayer HealthCare AG 51368 Leverkusen / DE
Former [2000/30]	For all designated states Bayer Aktiengesellschaft 51368 Leverkusen / DE
Inventor(s)	01 / Apeler, Heiner Dr. Neuer Triebel 71 42111 Wuppertal / DE
	02 / Wehlmann, Hermann Dr. Mastweg 3a 42349 Wuppertal / DE
	[2000/30]
Application number, filing date	99100967.1	20.01.1999
	[2000/30]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	EP1022339
	Date:	26.07.2000
	Language:	EN
	[2000/30]
	Type:	B1 Patent specification
	No.:	EP1022339
	Date:	01.02.2006
	Language:	EN
	[2006/05]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	07.07.1999
Classification	IPC:	C12N15/70, C12N15/72, C12N15/24, C07K14/54	[2000/30]
	CPC:	C07K14/5406 (EP,US); C12N15/11 (KR); C12N15/70 (EP,US); C12N15/72 (EP,US)
Designated contracting states	DE [2001/14]
Former [2000/30]	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
Title	German:	Plasmide, deren Konstruktion und Anwendung zur Herstellung von Interleukin-4 und dessen Muteine	[2000/30]
	English:	Plasmids, their construction and their use in the manufacture of interleukin-4 and interleukin-4 muteins	[2000/30]
	French:	Plasmides, leur construction et utilisation pour la préparation d'Interleukine-4 et ses mutéines	[2000/30]
Examination procedure	26.01.2001	Examination requested [2001/13]
	20.05.2003	Despatch of a communication from the examining division (Time limit: M04)
	20.08.2003	Reply to a communication from the examining division
	06.10.2003	Despatch of a communication from the examining division (Time limit: M04)
	01.03.2004	Reply to a communication from the examining division
	12.05.2004	Despatch of a communication from the examining division (Time limit: M04)
	01.10.2004	Reply to a communication from the examining division
	14.02.2005	Communication of intention to grant the patent
	24.06.2005	Fee for grant paid
	24.06.2005	Fee for publishing/printing paid
	29.07.2005	Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
Opposition(s)	03.11.2006	No opposition filed within time limit [2007/02]
Request for further processing for:	08.09.2005	Request for further processing filed
	09.09.2005	Full payment received (date of receipt of payment) Request granted
	12.10.2005	Decision despatched
	01.10.2004	Request for further processing filed
	06.10.2004	Full payment received (date of receipt of payment) Request granted
	22.10.2004	Decision despatched
	14.04.2004	Request for further processing filed
	14.04.2004	Full payment received (date of receipt of payment) Request granted
	29.04.2004	Decision despatched
Fees paid	Renewal fee
	31.01.2001	Renewal fee patent year 03
	31.01.2002	Renewal fee patent year 04
	31.01.2003	Renewal fee patent year 05
	02.02.2004	Renewal fee patent year 06
	31.01.2005	Renewal fee patent year 07
	31.01.2006	Renewal fee patent year 08
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[Y]US4689406 (BANKS ALLEN R [US], et al) [Y] 1-4 * abstract * * column 2, line 18 - column 4, line 23 *;
		[A]EP0241446 (MONSANTO CO [US]) [A] 1 * page 7, line 62 - page 9, line 58 *;
		[A]US5362646 (BUJARD HERMANN [DE], et al) [A] 1 * abstract * * Seq. c;; figure 54 *;
		[A]WO9608572 (RHONE POULENC RORER SA [FR], et al) [A] 1,4 * abstract * * page 4, line 27 - page 5, line 30 * * page 10; table 1 * * Seq.ID:1 nt.66-110; page 14 * * page 21 - page 22; claim - *;
		[A]WO9803654 (BAYER AG [US]) [A] 1,4 * page 4, line 25 - page 5, line 6 * * page 10, lines 4-30 *;
		[Y] - PTITSYN L.R. AND AL'TMAN I.B., "Recombinant Escherichia coli strains provide high-level expression of human Interleukin-3 and Interleukin-4", BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, (199501), vol. 119, no. 1, pages 77 - 79, XP002106664 [Y] 1-4 * page 77; figure 1 * * page 79, column L, paragraph 8 - column R, paragraph 1 *
		[AD] - HANNIG G. ET AL., "Strategies for optimizing heterologous protein expression in Escherichia coli", TRENDS IN BIOTECHNOLOGY, (19980201), vol. 16, no. 2, pages 54 - 60, XP004107042 DOI: http://dx.doi.org/10.1016/S0167-7799(97)01155-4
		[AD] - STUDIER F.W. ET AL., "Use of T7 RNA polymerase to direct expression of cloned genes", METHODS IN ENZYMOLOGY, (19900101), vol. 185, pages 60 - 89, XP000647676 [AD] 1 * page 74; figure 7 * DOI: http://dx.doi.org/10.1016/0076-6879(90)85008-C
		[A] - YOUNG YANG ET AL., "Production, purification and immuno-modulatory actions of E.coli-derived recombinant human interleukin 4", KOREAN BIOCHEMICAL JOURNAL, (1992), vol. 25, no. 1, pages 66 - 72, XP002106663 [A] 1,4 * page 68; figure 2 *
		[A] - LEVINE A.D. ET AL., "High level expression and refolding of mouse Interleukin 4 synthesized in Escherichia coli", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (19950331), vol. 270, no. 13, pages 7445 - 7452, XP002106665 [A] 1,4 * page 7447; figure 1 * DOI: http://dx.doi.org/10.1074/jbc.270.13.7445
		[A] - HANSSENS F. ET AL., "Expression, renaturation and purification of murine Interleukin 4 from E. coli", MEDELINGEN VAN DE FACULTEIT LANDBOUWWETENSCHAPPEN UNIVERSITEIT GENT, (1992), vol. 57, no. 4b, pages 2053 - 2061, XP002107061 [A] 1,4 * page 2054, paragraph 5 - page 2058, paragraph 1 *
	Examination	- MAKRIDES S.C., "Strategies for achieving high-level expression of genes in Escherichia coli", MICROBIOLOGICAL REVIEWS, (19960901), vol. 60, no. 3, pages 512 - 538

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p